NCT06943495 - Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 15, 2025

Primary Completion Date

March 31, 2029

Study Completion Date

March 31, 2033

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

177Lu-PSMA-617

6 cycles of personalized activity (1st cycle based on BSA and eGFR; cycles 2-6 based on renal dosimetry), maximum 22.2 GBq, every 6 weeks

DRUG

177Lu-PSMA-617

6 cycles of 7.4 GBq every 6 weeks

Trial Locations (1)

RECRUITING

CHU de Québec-Université Laval, Québec